Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug timing may boost immune attack on head and neck cancer

NCT ID NCT06052839

Recruiting now Disease control Sponsor: Dan Zandberg Source: ClinicalTrials.gov ↗

First seen Feb 22, 2026 · Last updated Apr 29, 2026 · Updated 9 times

Summary

This study tests a different way of giving chemotherapy together with the immunotherapy drug pembrolizumab for people with head and neck cancer that has come back or spread. The idea is that giving chemo in short, strong bursts after the immunotherapy might help the immune system fight the cancer better. The trial will enroll 15 adults whose cancer cannot be cured with local treatments and who have a certain marker (PD-L1 CPS >1). The main goal is to see how many patients are alive without their cancer growing after 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC)